JADEO: connecting the cannabis community

Published 03-MAY-2019 11:37 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

A couple of weeks ago, we reported on the fact that cannabis has become a commodity. We posited that commercial realities were setting in for many businesses that thought they would grow off of product partners and manufacturers.

JADEO is a Canadian publisher, helping cannabis companies, along with interested parties, connect with each other to weed out the wheat from the chuff.

We spoke with JADEO Director of Marketing Janelle Powell about the company and what it is trying to achieve.

Janelle Powell

Jonathan Jackson: What is JADEO's reason for being?

Janelle Powell: We wanted to create a safe place where people who were curious about cannabis or experienced with cannabis could connect, educate, learn and share. We wanted a place where the complex world of cannabis could be made simple. Hence why our motto is "Cannabis, made simple".

JJ. Who is behind it?

JP: JADEO is the brainchild of Michael Joseph and Connor Christine. It is a Canadian start-up based out of Toronto/Hamilton.

JJ. What are you ultimately trying to achieve?

JP: Ultimately, we want to normalize cannabis and end stigma. Although cannabis has been legalized in Canada a lot of negative stereotypes still persist. People still don't feel comfortable sharing their use or even just asking simple questions to educate themselves about cannabis. Our platform is the first step in making these types of interactions around cannabis normal.

JJ: Is the content aggregated, or is it a mix of aggregated and unique stories?

JP: As a platform, we create educational content ranging from articles to videos, but our members also create content. They share their experiences, write product and strain reviews, ask questions, share articles etc. It's a social network so you find that the members are being social around cannabis topics.

JJ: How does it work for advertisers?

JP: We offer a variety of packages for advertisers that can include banner ads, sponsored articles and/or videos. They can opt for full-service ad packages where we do all the creative or they can provide their own creative. Unlike mainstream platforms like Facebook, Instagram, etc. we obviously don't restrict cannabis content in our advertising allowing brands to better connect with their audience.

JJ: How do advertisers use the platform?

JP: As of right now, advertisers can use the platform to reach their target audience via our available packages. However, we do have some exciting things in the works for brands that we'll be releasing in an upcoming launch of the latest iteration of our platform. Brands can also use the account for social listening members are always asking about products or speaking about their experiences this creates an opportunity for brands to understand their audience's needs, wants, and hurdles.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X